A Phase 2/3 interventional study of Complete responders and Non-complete responders and Chemoradiation + EBRT Boost in Stage II Rectal Cancer, Organ Preservation and Non-operative Treatment, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Rectal Neoplasms with a site in Canada — 12 open to participants now, 21 under way, 6 of them phase 3. Rectal Neoplasms · Canada.
Among the 98 studies in Rectal Neoplasms with a site in Canada, this one is the 36th largest by planned enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2017, is one of 2 in phase 2/3, reaches primary completion later than 13 of the 20 other live ones, and was the 69th registered.
2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.
Browse Rectal Neoplasms studies →12 of the 98 studies in Rectal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Dr. Te Vuong · Sites in Canada
Ages 18+
GlaxoSmithKline · Sites in Canada, United States, Denmark and 6 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Canada, United States, Argentina and 26 more countries
Ages 18+
Canadian Cancer Trials Group · Sites in Canada, United States
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18–75
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 38 · Phase 3 26 · Phase 4 1
First in 1993; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 131 is above the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.
Median enrollment 95 across the 82 interventional studies, 1,076 across the 10 observational. Of the 66 that completed or were terminated, 13 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 98 have an industry lead sponsor. The 10 most frequent:
Sir Mortimer B. Davis - Jewish General Hospital is the lead sponsor of 62 studies on the registry; 22 are open to participants now.
Sir Mortimer B. Davis - Jewish General Hospital has 5 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Rectal Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00335816Memorial Sloan Kettering Cancer CenterRadiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | 2026-12 |
| NCT03179540Mount Sinai Hospital, CanadaNon-operative Management for Locally Advanced Rectal Cancer | 2026-12 |
| NCT05148494Nova Scotia Health AuthorityTES RCT Fleet Enema vs Oral Mechanical Bowel Prep | 2027-08-01 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 98 studies in Rectal Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).
It is becoming clear that there is a now an international consensus that rectal cancer research efforts need to be more focused in optimizing a non-surgical approach. This concept is very relevant to an ageing patient population with multiple co-morbidities regularly seen at the Jewish General Hospital and across the province. After interim analysis on 40 patients of the pilot study a phase III study is proposed. We are therefore proposing a phase III multicentric study of 145 patients to compare the two best known radiation dose escalation strategies and to achieve a complete clinical response. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions). Patients that have a high risk of recurrence or with more advanced stages of the disease will be excluded from the study, as only the local disease is being treated. The primary outcome for this proposal is rectum preservation in treated patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders
Procedure: Complete responders and Non-complete responders · Radiation: Chemoradiation + EBRT Boost
standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders
Procedure: Complete responders and Non-complete responders · Radiation: Chemoradiation + HDRBT Boost
Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
TME-free survival
Time from date of randomization to either TME or death in the intention to treat population
Time frame: 2 years post treatment
Local Recurrence
Number of participants with Local recurrence as assessed by tests during follow-up visits.
Time frame: 2 years post treatment
Disease-free survival
The time between the date of randomization and recurrence, either in the pelvis or metastases. Patients without an event will be censored at the last date the patient was known to be disease-free.
Time frame: 5 years post treatment
Overall survival
The time between date of randomization and date of death due to any causes.
Time frame: 5 years post treatment
Overall Quality of life
Quality of life Questionnaires over different time point
Time frame: 5 years post treatment
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2017 (actual). Primary completion is estimated for Jan 2028, 129 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sir Mortimer B. Davis - Jewish General Hospital